EFFICIENCY AND SAFETY ASSESSMENT OF GENERIC ATORVASTATINE IN PATIENTS WITH HYPERLIPIDEMIA

EFFICIENCY AND SAFETY ASSESSMENT OF GENERIC ATORVASTATINE IN PATIENTS WITH HYPERLIPIDEMIA

Aim. To assess in a short-term study efficiency and safety of hypolipidemic therapy with atorvastatine generic, Tulip, in comparison with simvastatine generic, Vasilip, in hyperlipidemic patients.Material and methods. Open, randomized, comparative, cross over study included 87 patients with hyperlip...

Full description

Saved in:

Bibliographic Details
Main Authors:	J. E. Semyonova, S. Y. Martsevich, N. V. Perova, A. M. Olferiev, N. P. Kutishenko, N. Y. Ivanenkova, N. A. Dmitrieva, A. A. Serazhim
Format:	Article
Language:	English
Published:	Столичная издательская компания 2015-12-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	hyperlipidemia hypolipidemic therapy simvastatine atorvastatine
Online Access:	https://www.rpcardio.online/jour/article/view/365
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

COMPARATIVE EFFICACY AND SAFETY OF HYPOLIPIDEMIC THERAPY WITH GENERIC AND ORIGINAL MEDICINAL PRODUCTS OF SIMVASTATIN
by: E. I. Tarlovskaya, et al.
Published: (2016-01-01)

Lipid-lowering effectiveness of a Russian generic of atorvastatin in patients with various hyperlipidaemia phenotypes
by: P. P. Malyshev, et al.
Published: (2009-12-01)

EFFICACY AND SAFETY OF THERAPY WITH ATORVASTATIN IN HIGH DOSES
by: A. N. Meshkov
Published: (2016-01-01)

EFFECT OF SIMVASTATIN ON MARKERS OF CARDIOVASCULAR RISK
by: N. V. Perova, et al.
Published: (2016-01-01)

COMPARISON OF EFFICACY AND TOLERABILITY OF ORIGINAL AND GENERIC DRUGS OF SIMVASTATIN IN PATIENTS WITH HYPERLIPIDAEMIA AND HIGH RISK OF ISCHEMIC HEART DISEASE COMPLICATIONS
by: S. N. Tolpygina, et al.
Published: (2016-01-01)

Effects of Fenugreek Supplement on Liver Enzymes Level in P-407 Induced Hyperlipidemia in Wistar Rats
by: Abdulrazak, A. , Tanko, Y. , Kabiru, A. and Sada, M.N.
Published: (2019-12-01)

Secondary hyperlipidemias: etiology and pathogenesis
by: A. I. Ershova, et al.
Published: (2019-06-01)

ATORVASTATIN — 20 YEARS IN THE STRUGGLE FOR LIFE
by: N. G. Gogolashvili
Published: (2018-03-01)

IMPORTANCE OF THE LEPTIN/GRELIN RATIO AS A BIOMARKER IN DIETARY INDUCED HYPERLIPIDEMIA IN FEMALE C57Black/6 MICE
by: N. A. Riger, et al.
Published: (2018-06-01)

Atorvastatin: evidence base 15 years later
by: A. V. Susekov, et al.
Published: (2011-06-01)

THE EFFECTIVENESS OF OUTPATIENT AND HOSPITAL LIPID-LOWERING THERAPY IN PATIENTS WITH HIGH AND VERY HIGH CARDIOVASCULAR RISK DURING 2011-2015
by: S. A. Smetnev, et al.
Published: (2017-01-01)

A COMPARATIVE STUDY OF EFFICACY AND TOLERABILITY OF ORIGINAL AND GENERIC SIMVASTATIN IN PATIENTS WITH HYPERLIPIDEMIA
by: V. P. Voronina, et al.
Published: (2016-01-01)

Aggressive statin therapy in acute coronary syndrome: therapeutic potential of atorvastatin in the daily dose of 80 mg
by: A. N. Britov
Published: (2009-12-01)

Occurrence of hyperlipidemia in relation to body mass index in school children aged 9–11
by: Łukasz Szternel, et al.
Published: (2015-12-01)

STATINS AND PERCUTANEOUS CORONARY INTERVENTION. FOCUS ON THE ATORVASTATIN
by: N. G. Gogolashvili
Published: (2015-09-01)

Research Progress and Prospects of Flavonoids in the Treatment of Hyperlipidemia: A Narrative Review
by: Xingtong Chen, et al.
Published: (2025-07-01)

Comparison of treatment patterns, efficacy and safety between generic and branded atorvastatin users in China: a multicenter, retrospective propensity score-matched cohort study
by: Xiaoxuan Xing, et al.
Published: (2025-07-01)

Safety of Lipid-Lowering Therapy with Statins according to a Regional Pharmacovigilance Centre
by: E. O. Kochkina, et al.
Published: (2023-09-01)

Short Term Comparison Between Safety and Efficacy of Rosuvastatin 40 mg and Atorvastatin 80 mg in Patients with Acute Coronary Syndrome
by: Sh. A. Mostafa, et al.
Published: (2018-11-01)

THE USE OF ATORVASTATIN FOR THE PREVENTION OF RECURRENT ATRIAL FIBRILLATION AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: S. N. Tereshchenko, et al.
Published: (2016-01-01)

Organisms Producing Hypolipidemic Compounds with Antioxidant Activity
by: T. O. Puzhevskaya, et al.
Published: (2020-05-01)

Pharmacoeconomic Analysis of Therapy with Generic Statin Drugs in Patients with High and Very High Cardiovascular Risk (According to the Study PRIORITY)
by: S. Yu. Martsevich, et al.
Published: (2020-11-01)

Effect of Alcoholic Catechin Extract on Hyperglycemia, Hyperlipidemia and Liver Functions in Alloxan Diabetic Mice
by: Baghdad Science Journal
Published: (2014-09-01)

A case of rhabdomyolysis after atorvastatin therapy of a liver transplant recipient receiving immunosuppressive therapy with cyclosporine
by: A. V. Shabunin, et al.
Published: (2021-06-01)

Fabrication and evaluation of solidified nanoemulsion designs for systemic delivery of atorvastatin through the lung
by: Muhammad Danish Saeed, et al.
Published: (2025-07-01)

Ginkgolide B attenuates hyperlipidemia by restoring sphingolipid homeostasis and activating PPARα and Nrf2 pathways
by: Yun Liu, et al.
Published: (2025-08-01)

Exploring the mechanism of Taohong Siwu decoction in the treatment of hyperlipidemia based on network pharmacology and zebrafish models
by: Mingyang Li, et al.
Published: (2025-06-01)

Statinotherapy – the paradigm of prevention and treatment of atherosclerotic pathology (focus on atorvastatin)
by: R. G. Oganov, et al.
Published: (2006-12-01)

Cholesterol-modulating effects of Korean red ginseng (KRG) targeting PCSK9 in hyperlipidemia
by: Chang Hwan Lee, et al.
Published: (2025-08-01)

The effect of Gougunao tea polysaccharide on lipid metabolism in hyperlipidemia induced by a high-fat diet and its structural characteristics
by: Qihuan Deng, et al.
Published: (2025-01-01)

EFFECTS OF ATORVASTATIN ON ENDOTHELIAL DYSFUNCTION IN TYPE 2 DIABETIC PATIENTS WITH DIFFERENT DURATION F THE DISEASE
by: G. A. Batrak, et al.
Published: (2015-09-01)

RESULTS OF THE CLINICAL TRIAL FOURIER. NEW OPPORTUNITIES FOR TREATMENT OF VERY HIGH CARDIOVASCULAR RISK PATIENTS
by: Advisory Board
Published: (2017-06-01)

SPECIFICS OF LIPID METABOLISM AND ATORVASTATIN EFFICACY IN TYPE 2 DIABETES WITH CARRIAGE OF VARIOUS POLYMORPHISMS OF CHOLESTEROL ETHER CARRYING PROTEIN TaqIB GENE
by: M. V. Kim, et al.
Published: (2015-10-01)

ACUTE ATORVASTATIN RECAPTURE THERAPY IN CORONARY ARTERY BYPASS GRAFTING
by: A. V. Panov, et al.
Published: (2017-07-01)

TREATMENT OF PATIENTS WITH SEVERE DYSLIPIDEMIA IN REAL CLINICAL PRACTICE
by: V. A. Korneva, et al.
Published: (2015-09-01)

A Molecular and Biochemical Study for Cholesteryl Ester Transfer Protein (CETP) Taq1B in Iraqi Patients with Hyperlipidemia
by: Alkhafajy et al.
Published: (2019-09-01)

Efficacy of atorvastatin therapy in prevention of postoperative atrial fibrillation in patients with ischemic heart disease
by: O. A. Rubanenko
Published: (2015-11-01)

EFFECT OF GENES SLCO1B1 AND MDR1 POLYMORPHISM ON ATORVASTATIN PHARMACOKINETICS AND PHARMACODYNAMICS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: RESULTS OF PILOT PHARMACOGENETICS STUDY
by: A. V. Semenov, et al.
Published: (2016-01-01)

NEWS OF EVIDENCE-BASED MEDICINE: RESULTS OF THE IMPROVE-IT TRIAL AND THEIR IMPLICATIONS FOR CLINICAL PRACTICE
by: S. Yu. Martsevich
Published: (2015-09-01)

Targeting hyperlipidemia: A polarity-driven ternary extraction of Apium graveolens bioactives—A coupled in-vivo, in-vitro and in-silico investigation
by: Nargis Sultana Chowdhury, et al.
Published: (2025-08-01)